Next Article in Journal
Polyhydroxylated Steroids from the Bamboo Coral Isis hippuris
Previous Article in Journal
High-Value Components and Bioactives from Sea Cucumbers for Functional Foods—A Review

Marine Drugs 2011, 9(10), 1806-1828; doi:10.3390/md9101806

Fucoxanthin, a Marine Carotenoid Present in Brown Seaweeds and Diatoms: Metabolism and Bioactivities Relevant to Human Health
Juan Peng , Jian-Ping Yuan *, Chou-Fei Wu and Jiang-Hai Wang *
Guangdong Provincial Key Laboratory of Marine Resources and Coastal Engineering, School of Marine Sciences, Sun Yat-Sen University, Guangzhou 510275, China; E-Mails: (J.P.); (C.-F.W.)
Authors to whom correspondence should be addressed; E-Mails: (J.-P.Y.); (J.-H.W.); Tel.: +86-20-39332212; Fax: +86-20-39332213.
Received: 6 September 2011; in revised form: 21 September 2011 / Accepted: 21 September 2011 /
Published: 10 October 2011


: The marine carotenoid fucoxanthin can be found in marine brown seaweeds, the macroalgae, and diatoms, the microalgae, and has remarkable biological properties. Numerous studies have shown that fucoxanthin has considerable potential and promising applications in human health. In this article, we review the current available scientific literature regarding the metabolism, safety, and bioactivities of fucoxanthin, including its antioxidant, anti-inflammatory, anticancer, anti-obese, antidiabetic, antiangiogenic and antimalarial activities, and its protective effects on the liver, blood vessels of the brain, bones, skin, and eyes. Although some studies have shown the bioavailability of fucoxanthin in brown seaweeds to be low in humans, many studies have suggested that a dietary combination of fucoxanthin and edible oil or lipid could increase the absorption rate of fucoxanthin, and thus it might be a promising marine drug.
fucoxanthin; metabolite; bioactivity; brown seaweed; diatom

1. Introduction

Fucoxanthin is one of the most abundant carotenoids, and contributes more than 10% of the estimated total production of carotenoids in nature, especially in the marine environment [1]. Fucoxanthin is an orange-colored pigment, along with chlorophylls a and c and β-carotene, present in Chromophyta (Heterokontophyta or Ochrophyta), including brown seaweeds (Phaeophyceae) and diatoms (Bacillariophyta) [2,3]. Fucoxanthin was first isolated from the marine brown seaweeds Fucus, Dictyota, and Laminaria by Willstätter and Page [4] in 1914. The complete structure (Figure 1) of fucoxanthin including chirality was determined by Englert et al. [5]. Some brown seaweeds are the most common edible macroalgae in South-East Asia and a few European countries [6]. Diatoms are unicellular planktonic microalgae and exhibit a characteristic golden-brown color due to a high amount of fucoxanthin that plays a major role in the light-harvesting complex of photosystems [7].

Fucoxanthin has been isolated for its bioactivity studies from the marine brown seaweeds Alaria crassifolia [8], Cladosiphon okamuranus [9], Cystoseira hakodatensis [8,10], Eisenia bicyclis [8], Fucus serratus [11], Fucus vesiculosus [12], Hijikia fusiformis [13,14], Ishige okamurae [15], Kjellmaniella crassifolia [8], Laminaria japonica [1618], Laminaria ochotensis [18], Myagropsis myagroides [19], Padina tetrastromatica [6], Petalonia binghamiae [20], Sargassum fulvellum [14], Sargassum heterophyllum [21], Sargassum horneri [10], Sargassum siliquastrum [22], and Undaria pinnatifida [10,14,2332], and the diatoms Chaetoseros sp. [33,34], Cylindrotheca closterium [35], Odontella aurita [36], and Phaeodactylum tricornutum [2].

Fucoxanthin has remarkable biological properties based on its unique molecular structure similar to neoxanthin, dinoxanthin, and peridinin, which is different from that of other carotenoids such as β-carotene and astaxanthin. Fucoxanthin has an unusual allenic bond and some oxygenic functional groups such as epoxy, hydroxyl, carbonyl and carboxyl moieties in its molecule (Figure 1) that contribute to its unique structure [2,14]. The allenic bond was found mainly in carotenoids such as fucoxanthin, which was the first allenic carotenoid found in brown seaweeds [1], and was responsible for the higher antioxidant [27].

This article reviews the current available scientific literature regarding the metabolism, safety, and bioactivities of fucoxanthin, including its antioxidant, anti-inflammatory, anticancer, anti-obese, antidiabetic, antiangiogenic and antimalarial activities, and its protective effects on the liver, blood vessels of the brain, bones, skin, and eyes.

2. Bioavailability, Metabolism, and Safety of Fucoxanthin

2.1. Bioavailability and Metabolism of Fucoxanthin

Solubilization of carotenoids in mixed micelles is considered to be requirement for absorption by intestinal cells. Sugawara et al. [37] demonstrated that phospholipids had intense effects on carotenoid absorption, and the cellular absorption was dependent on the lipophilicity of carotenoids. This study suggested that pancreatic phospholipase A2 and lysophosphatidylcholine were crucial in modulating the absorption of carotenoids in the gastrointestinal tract and supported a simple diffusion mechanism for carotenoid assimilation by the intestinal epithelium. It was suggested that fucoxanthin was more readily absorbed than lutein esters in mouse intestine [38] and its metabolites were accumulated in the body at a higher ratio than astaxanthin [39].

It had been previously reported that ingested fucoxanthin was totally deacetylated in the instestinal lumen and transported via blood in White leghorn laying hens fed the brown seaweed F. serratus, and thus fucoxanthinol was present as one of the main carotenoids in egg yolk [11]. Sugawara et al. [40] showed that fucoxanthin was hydrolyzed to fucoxanthinol during the uptake by differentiated Caco-2 cells, a tissue culture model for studying the absorption of dietary compounds by human intestinal epithelium. This study also showed fucoxanthinol appeared in mouse plasma after ingestion of fucoxanthin, indicating that dietary fucoxanthin was deacetylated into fucoxanthinol in the intestinal tract by lipase and esterase from the pancreas or in intestinal cells, and incorporated as fucoxanthinol from the digestive tract into the blood circulation system in mammals. Therefore, the bioavailability of fucoxanthinol is higher than that of fucoxanthin in the body [41].

Asai et al. [42] investigated further biotransformation of fucoxanthinol in ICR mice and HepG2 cells, and revealed that an unknown metabolite had been previously found in marine tunicate Amaroucium pliciferum, and thus was identified as amarouciaxanthin A (Figure 1). The bioconversion of fucoxanthinol into amarouciaxanthin A through dehydrogenation/isomerization was principally shown in liver microsomes, and fucoxanthinol supplemented to culture medium via HepG2 cells was also converted into amarouciaxanthin A. Therefore, it was suggested that fucoxanthin was converted to fucoxanthinol in the gastrointestinal tract and was then metabolized to amarouciaxanthin A in the liver [6,10,39,4244], and no fucoxanthin was detected in plasma and liver [42,44]. Hashimoto et al. [39] found that fucoxanthinol and amarouciaxanthin A were detectable in plasma, erythrocytes, the liver, lungs, kidney, heart, spleen, and adipose tissue in ICR mice fed 160 nmol fucoxanthin, whereas no fucoxanthin was detected in these tissues or in the blood.

However, the daily oral administration of fucoxanthin for 1 week showed that a small amount of fucoxanthin was not metabolized and was detectable in the liver, lung, kidney, heart, spleen, and adipose tissue of the mice [39]. The percentage of fucoxanthin, fucoxanthinol, and amarouciaxanthin A to the sum of all of these in the adipose tissue was 13, 32, and 55%, respectively, while the percentage in the other tissues was 1–11, 63–76 and 20–26%, respectively [39], indicating that amarouciaxanthin A accumulated preferentially in the adipose tissue [10,38,39], while fucoxanthinol accumulated mainly in the liver, lungs, kidney, heart, and spleen [39]. Yonekura et al. [38] showed that fucoxanthinol and amarouciaxanthin A accumulated mainly in adipose tissues (3.13–3.64 μmol/kg), in which the contents were 2.2- to 2.6-fold of that in plasma, liver, and kidney (1.29–1.80 μmol/kg) in ICR mice fed 128 nmol fucoxanthin daily for 14 days.

Further transformation of amarouciaxanthin A to more polar metabolites might be taking place in ICR mice [38]. Sangeetha et al. [6] reported in detail on various metabolites of fucoxanthin besides the major metabolites fucoxanthinol and amarouciaxanthin A in rats, proposed a possible metabolic pathway of fucoxanthin in the plasma and liver of rats, and speculated that these metabolites might be formed as a result of enzymatic reactions such as isomerization, dehydrogenation, deacetylation, oxidation, and demethylation.

In addition, in marine animals such as oysters and clams [4547], fucoxanthinol was further metabolized into halocynthiaxanthin (Figure 1), which was first isolated from sea squirt Halocynthia roretzi [48,49].

In a human study, Asai et al. [28] determined the plasma concentrations of fucoxanthin metabolites before and after 1-week dietary interventions with U. pinnatifida to estimate the intestinal absorption of fucoxanthin in five healthy volunteers. The results showed that the plasma concentration of fucoxanthinol was low (0.8 nmol/L) after 1 week of uptake (6.1 mg fucoxanthin/day), and no fucoxanthin and amarouciaxanthin A was detected in the plasma, and it was possible that some components (e.g., dietary fibre) in algal matrix inhibited the intestinal absorption of fucoxanthin.

It has been suggested that dietary combination of fucoxanthin and edible oil or lipid could increase the absorption rate of fucoxanthin in KK-Ay mice [32,50,51] and in obese premenopausal women [52].

2.2. Safety of Fucoxanthin

Fucoxanthin and fucoxanthinol had few adverse effects on normal and uninfected cells both in vitro and in vivo [53,54]. Zaragozá et al. [12] studied the toxicity of extracts from F. vesiculosus in mice and rats, and indicated that even at the dose of 750 mg/kg daily for 4 weeks, no any relevant signs of toxicity occurred. Kadekaru et al. [55] conducted a toxicity study on the repeated oral dosing of fucoxanthin (95% purity) to rats for 28 days, and revealed that fucoxanthin did not show obvious toxicity.

Beppu et al. [3] conducted a single dose toxicity study at doses of 1000 and 2000 mg/kg and a repeated oral dose toxicity study at doses of 500 and 1000 mg/kg for 30 days on purified fucoxanthin (93% purity) in ICR mice. The results showed that no mortality and no abnormalities in gross appearance were found in both studies, and no abnormal changes in liver, kidney, spleen, and gonadal tissues induced by fucoxanthin in the histological observations of the repeated doses study. Subsequently, Beppu et al. [56] indicated that fucoxanthin had no genotoxic/mutagenic effect on the bone marrow cells of mice. Iio et al. [33,34] investigated the subchronic toxicity of fucoxanthin in rats and genotoxicity in mice. In the single oral dose study, no mortality and no change were observed. The 50% lethal dose of fucoxanthin was more than 2000 mg/kg body weight. In the 13-week oral dose study, the no-observed-adverse-effect level of fucoxanthin was 200 mg/kg body weight under the tested subchronic dose condition. These studies suggested that fucoxanthin was a safe compound and did not exhibit toxicity and mutagenicity under these experimental conditions [3,34,56].

However, some carotenoids may have ability to increase circulating cholesterol level in rodents as a common feature [3]. Although fucoxanthin markedly elevated plasma high-density lipoprotein cholesterol level [3,55,57], total cholesterol level in the blood significantly increased to the same degree while the dose of fucoxanthin was 50 mg/kg daily for 28 days in Crl:CD (SD) rat and 1000 mg/kg daily for 30 days in ICR mice [3,55]. To further ascertain the safety of fucoxanthin, the mechanism by which fucoxanthin induces hypercholesterolemia and species differences should be elucidated.

3. Potential Health-Promoting Effects of Fucoxanthin

3.1. Antioxidant Activity

Antioxidant activity is one of the important characteristics of carotenoids, and many of their biological effects are related to the ability to scavenge reactive oxygen species, which is one of the factors for their disease preventing effects [27]. Earlier studies had indicated that fucoxanthin was also an effective radical scavenger [2,14]. The chemically generated radicals used to evaluate the antioxidant activity of fucoxanthin include DPPH (1,1-diphenyl-2-picrylhydrazyl), 12-DS (12-doxyl-stearic acid), NB-L (the radical adduct of nitrosobenzene with linolenic acid radical), AAPH (2,2′-azo-bis- (2-amidinopropane) dihydrochloride), ABTS (2,2′-azinobis-3-ethylbenzothiazoline-6-sulphonate), and ABAP (2,2′-azo-bis-2-amidinopropane) [8,12,13,27].

It has been reported that the extracts of H. fusiformis, C. okamuranus, U. pinnatifida, and S. fulvellum showed a strong DPPH radical scavenging activity [9,14]. Recently, Airanthi et al. [8] showed that the methanol extract of C. hakodatensis was a good source for antioxidants and the high antioxidant activity was based not only on the high content of phenolics, but also on the presence of fucoxanthin, demonstrating the synergy in the antioxidant activity of phenolics and fucoxanthin. Although two extracts from F. vesiculosus containing 28.8% polyphenols or 18% polyphenols and 0.0012% fucoxanthin, respectively, exhibited antioxidant activity in noncellular systems (O2 •−, DPPH, ABTS, and ABAP) and in activated RAW 264.7 macrophages, as well as in ex vivo assays in plasma and erythrocytes, after the 4-week treatment in rats, only extract containing fucoxanthin showed an antioxidant activity ex vivo through preventing oxidant formation, scavenging superoxide anion (O2 •−), and reducing active intermediates [12].

It was shown that fucoxanthin scavenged organic free radicals 12-DS, DPPH, and NB-L with the inhibitions of 66% (incubation for 12 h), 28% (1 h), and 57% (12 h), respectively, in the electron spin resonance signal intensities [13]. Fucoxanthin could effectively inhibit intracellular reactive oxygen species formation, DNA damage, and apoptosis induced by H2O2, possibly due to the ability of fucoxanthin to increase catalase [22].

Sachindra et al. [27] assessed the antioxidant activities of fucoxanthin and its two metabolites, fucoxanthinol and halocynthiaxanthin, in vitro with respect to radical scavenging (DPPH, ABTS, hydroxyl radical, and superoxide radical) and singlet oxygen quenching abilities, and suggested that fucoxanthin and fucoxanthinol exhibited antioxidant activities higher or similar to that of α-tocopherol, and halocynthiaxanthin showed comparatively lower antioxidant activities. The hydroxyl radical scavenging activity of fucoxanthin was 7.9, 16.3, and 13.5 times higher than that by fucoxanthinol, halocynthiaxanthin, and α-tocopherol, respectively, but singlet oxygen quenching ability of fucoxanthin was lower than that of β-carotene. Although halocynthiaxanthin showed very poor scavenging activity, of 19 carotenoids including halocynthiaxanthin, fucoxanthinol, astaxanthin, canthaxanthin, lutein, and β-carotene, halocynthiaxanthin showed the highest suppressive effect on superoxide anion (O2 •−) and nitric oxide (NO) generation from differentiated human promyelocytic HL-60 cells and mouse macrophage RAW 264.7 cells, respectively [45].

Burton and Ingold [58] previously pointed out that β-carotene exhibited good radical-trapping antioxidant activity only at partial pressures of oxygen significantly less than the pressure of oxygen in normal air, which is found in most tissues under physiological conditions. Nomura et al. [2] found that, under anoxic conditions, fucoxanthin equimolarly reacted with DPPH as radical quencher, whereas β-carotene, β-cryptoxanthin, zeaxanthin, licopene, and lutein scarcely reacted with DPPH and had practically no quenching activities, suggesting that fucoxanthin was more reactive to radicals than other carotenoids under anoxic conditions. However, under aerobic conditions, only a part of fucoxanthin consumed DPPH and fucoxanthin was relatively less sensitive than β-carotene. Under a high oxygen pressure, e.g., 100 kPa, fucoxanthin had much less antioxidant activity than α-tocopherol for the oxidation of methyl linoleate in heptanol in the presence of 2,2′-azo-bis-iso-butyronitrile at 60 °C [59].

Sangeetha et al. [44,60] compared the effects of fucoxanthin and β-carotene on oxidative stress indicators (catalase, glutathione transferase, and Na+K+-ATPase) and the possible role in suppressing lipid peroxidation resulting from retinol deficiency in rats. The results showed that fucoxanthin and β-carotene protected cell membrane by decreasing Na+K+-ATPase activity and increasing the activities of catalase and glutathione transferase at the tissue and microsomal level affected by retinol deficiency possibly due to its antioxidant activity, thus protecting membranes against lipid peroxidation caused by retinol deficiency. The results also showed that fucoxanthin had greater potential than β-carotene and was somewhat more effective than retinol in reducing lipid peroxidation in plasma and liver resulting from retinol deficiency. Li et al. [61] showed that vitamin D2 was oxidized by singlet oxygen in the presence of riboflavin, light, and oxygen in a model system, and fucoxanthin and β-carotene could minimize the oxidation of vitamin D2 by quenching singlet oxygen.

The major structural differences in fucoxanthin and other carotenoids are the presence of an unusual allenic carbon (C-7′), 5,6-monoepoxide, two hydroxyl groups, a carbonyl group, and an acetyl group in the terminal ring of fucoxanthin [2,14]. The allenic bond was responsible for the higher antioxidant activity of fucoxanthin [27]. In addition, fucoxanthin has six oxygen atoms, and thus might be more sensitive to radicals, especially under anoxic conditions. It has been suggested that the antioxidant activity of carotenoids is correlated with the presence of intramolecular oxygen atoms [2].

It is worth mentioning that fucoxanthin also contains an α,β-unsaturated carbonyl group, and may function as a Michael acceptor which can react with important proteins such as Keap 1 in the Nrf2 system [62]. Liu et al. [62] recently showed that fucoxanthin enhanced HO-1 and NQO1 expression in murine hepatic BNL CL.2 cells through activation of the Nrf2/ARE system, and suggested that fucoxanthin might exert its antioxidant activity, at least partly, through its pro-oxidant actions.

3.2. Anti-Inflammatory Effects

Inflammatory response, a self-defensive reaction against various pathogenic stimuli, is characterized by attracting large amounts of leukocytes (neutrophiles, monocytes-macrophages, and mast cells) to the inflamed area, in which these inflammatory cells are triggered by inflammation mediators and generate superoxide anion and nitric oxide radicals, and may become a harmful self-damaging process [12,63]. Anti-inflammatory agents should reduce the inflammatory response by suppressing the productions of inflammatory cytokines such as tumor necrosis factor-α, interleukin-1β, and interleukin-6, and inflammatory mediators, including nitric oxide and prostaglandin E2 synthesized by inducible nitric oxide synthase and cyclooxygenase [64].

Heo et al. [22] and Kim et al. [65] authenticated the inhibitory effects of fucoxanthin on inflammatory cytokines and mediators in lipopolysaccharide-stimulated RAW 264.7 macrophages. These results showed that fucoxanthin inhibited the inducible nitric oxide synthase and cyclooxygenase 2 protein expressions, and reduced the levels of nitric oxide, prostaglandin E2, tumor necrosis factor-α, interleukin-1β, and interleukin-6 through the inhibition of nuclear factor-κB activation and the phosphorylation of mitogen-activated protein kinases [22,65].

Sakai et al. [66] indicated that fucoxanthin suppressed the degranulation of mast cells by inhibiting antigen-induced aggregation of high affinity IgE receptor followed by activation of the degranulating signals of mast cells, which played important roles in inflammation and immediate-type allergic reactions. Recently, Sakai et al. [67] evaluated the effect of carotenoids on dinitrofluorobenzene-induced contact hypersensitivity in mice to elucidate their effect on mast cell degranulation in vivo, and showed that fucoxanthin significantly inhibited ear swelling and reduced the levels of tumor necrosis factor-α and histamine, suggesting that fucoxanthin exerted an anti-inflammatory effect by suppressing mast cell degranulation in vivo.

Khan et al. [29,68] investigated the anti-inflammatory activity of methanol extract of U. pinnatifida against mouse ear edema and erythema induced by phorbol myristate acetate. The results showed that the extract suppressed edema and erythema with relative inhibition of 85 and 78%, respectively [68], and inhibited erythema by 50% when applied within 1 h before or 15 min after application of phorbol myristate acetate [29]. In addition, the extract suppressed the acetic acid-induced writhing response in the analgesic test, and also demonstrated antipyretic activity in yeast-induced hyperthermic mice [69].

3.3. Anticancer Activity

Apoptosis induction has been suggested to be the biochemical mechanism by which fucoxanthin exerted an inhibitory effect on tumor cells [23,25,31,70,71]. The apoptosis-inducing effect of fucoxanthin on human promyelocytic leukemia HL-60 cell line has been investigated by Hosokawa et al. [23], who found that fucoxanthin exhibited strong antiproliferative activity and could induce apoptosis of HL-60 cells. In HL-60 cells, fucoxanthin caused cleavages of procaspase-3 and poly-ADP-ribose polymerase, and apoptosis induction by fucoxanthin was mediated through mitochondrial membrane permeabilization and caspase-9 and caspase-3 activation [72]. Kim et al. [15] showed that fucoxanthin induced reactive oxygen species generation, inactivated the Bcl-xL signaling pathway, induced caspase-3, -7, and poly-ADP-ribose polymerase cleavage, and thus triggered the apoptosis of HL-60 cells, indicating that the generation of reactive oxygen species was a critical target in fucoxanthin-induced apoptosis in HL-60 cells.

It had been reported that β-carotene did not show an apoptosis-inducing effect on HL-60 cells, indicating that the carotenoid structure might be crucial for inducing apoptosis [23]. Recently, Ganesan et al. [73] showed that fucoxanthin, astaxanthin, siphonaxanthin, neoxanthin, and violaxanthin had significant cytotoxic effects against cultured HL-60 cells and the inhibitory effect of fucoxanthin on the viability of HL-60 cells was remarkable compared with astaxanthin, β-carotene, zeaxanthin, lutein, etc. Both halocynthiaxanthin and fucoxanthinol showed remarkable induction of apoptosis in HL-60 cells, MCF-7 breast cancer cells, and Caco-2 colon cancer cells, and the antiproliferative and apoptosis-inducing effects of halocynthiaxanthin and fucoxanthinol on these cells were significantly greater than those of fucoxanthin, possibly at least partly, related to the hydroxyl group in halocynthiaxanthin and fucoxanthinol [49]. Both fucoxanthinol and amarouciaxanthin A also reduced the viability of PC-3 human prostate cancer cells, and the 50% inhibitory concentrations of fucoxanthin, fucoxanthinol, and amarouciaxanthin A on the proliferation of PC-3 cells were 3.0, 2.0, and 4.6 μM, respectively, indicating that the 5,6-epoxide in fucoxanthin and fucoxanthinol played important roles in cytotoxicity, and other mechanisms might be also involved in the antiproliferative effect of epoxycarotenoids on PC-3 cells [42].

Adult T-cell leukemia is an incurable malignancy of mature CD4+ T cells caused by human T-cell leukemia virus type 1. Ishikawa et al. [53] assayed the antiproliferative effects of some carotenoids such as fucoxanthin, fucoxanthinol, β-carotene and astaxanthin, and found that both fucoxanthin and fucoxanthinol had remarkable antiproliferative effects on human T-cell leukemia virus type 1-infected T-cell lines and adult T-cell leukemia cells in vitro, and β-carotene and astaxanthin had mild inhibitory effects.

The exposure of human non-small-cell bronchopulmonary carcinoma line NSCLC-N6 and human lung epithelial cell line A549 to fucoxanthin distinctly induced morphological change such as rounding up, reduction of cell volume, chromatin condensation, nuclei fragmentation, and formation of apoptotic bodies for the two bronchopulmonary cells lines, and suggested that fucoxanthin could trigger the terminal differentiation of cancerous cells in vitro [36].

It was reported that fucoxanthin reduced the viability of human colon cancer cell lines Caco-2, HT-29, and DLD-1 cells (Caco-2 > DLD-1 > HT-29) and induced apoptosis in a dose- and time-dependent manner, while astaxanthin and β-carotene were not found to change the viability of Caco-2 cells. The decreased expression level of Bcl-2 protein might contribute to fucoxanthin-induced apoptosis in Caco-2 cells [25]. Kotake-Nara et al. [71] evaluated the effects of fucoxanthin and neoxanthin on the viability of human colorectal carcinoma Caco-2, human colorectal adenocarcinoma HCT116 cell lines, mouse melanoma B16, human normal embryonic lung fibroblast MRC-5, and human male umbilical cord fibroblast HUC-Fm cell lines. The results showed that fucoxanthin and neoxanthin had nearly the same actions on the cultured cells and were more effective in reducing the viability of HCT116 cancer cells than that of the other cancer and normal cell lines, while lycopene was found to be less effective. Das et al. [74] indicated that fucoxanthin inhibited the proliferation of human colon cancer cell lines WiDr and HCT116 cells by inducing cell cycle arrest at the G0/G1 phase through up-regulating the cyclin-dependent kinase inhibitory protein p21WAF1/Cip1 and retinoblastoma protein (pRb).

Kotake-Nara et al. [70] showed that fucoxanthin significantly reduced the viability of three human prostate cancer cell lines PC-3, DU 145 and LNCaP to 14.9%, 5.0%, and 9.8%, respectively, through apoptosis induction in these cancer cells. The succeeding study demonstrated that fucoxanthin decreased the levels of Bax and Bcl-2 proteins, and induced apoptosis in PC-3 cells through caspase-3 activation [71,75]. Satomi and Nishino [76] showed that fucoxanthin induced cell cycle arrest at the G1 phase and GADD45A expression, and inhibited the growth of DU145 cells. The results suggested that GADD45A and Pim-1 protooncogene might be important genes associated with the action of fucoxanthin, and GADD45A might be involved in fucoxanthin-induced G1 arrest. In the subsequent study, Satomi and Nishino [77] showed that several MAPKs modulated the induction of GADD45 and G1 arrest, and positive regulation by SAPK/JNK was involved in GADD45A induction and G1 arrest by fucoxanthin, indicating that GADD45A was closely related with the G1 arrest induced by fucoxanthin, and MAPK pathways were implicated in fucoxanthin-induced GADD45A expression and G1 cell cycle arrest in tumor cells depending on the cell type.

Satomi and Nishino [76] previously showed that fucoxanthin inhibited the growth of human hepatocellular carcinoma HepG2 cells. In the subsequent study, Satomi and Nishino [77] investigated the role of MAPKs in the induction of G1 arrest and GADD45 expression by fucoxanthin in HepG2 cells, and showed that the inhibitions of p38 MAPK and ERK1/2 MAPK enhanced the induction of GADD45A and GADD45B expressions, respectively, and GADD45A was an important factor in the induction of G1 arrest by fucoxanthin in HepG2 cells. The molecular mechanisms of fucoxanthin against hepatocellular carcinoma using HepG2 cells had been studied by Das et al. [16], who found that the growth-inhibitory effect of fucoxanthin on the cancer cells was chiefly due to an arrest in the G0/G1 phase of the cell cycle, and no apoptosis was observed, indicating that fucoxanthin possessed cytostatic rather than cytocidal activity in HepG2 cells. This study suggested that both the proteolysis and transcriptional suppression might be responsible for the decreasing levels of cyclin Ds and the suppression of cyclin D/cdk4 activity in fucoxanthin-treated HepG2 cells and might be related to the antitumor activity. Liu et al. [30] indicated that fucoxanthin effectively inhibited the proliferation of human hepatoma SK-Hep-1 cells but facilitated the growth of murine embryonic hepatic BNL CL.2 cells. The study found that fucoxanthin significantly increased protein and mRNA expressions of connexin 43 and connexin 32 in SK-Hep-1 cells, and thus enhanced gap junctional intercellular communication of SK-Hep-1 cells, which might be responsible for the increase of the intracellular calcium level, leading to cell cycle arrest at G0/G1 phase, DNA fragmentation, and apoptosis of SK-Hep-1 cells.

Recently, the effects of fucoxanthin on human gastric adenocarcinoma MGC-803 cells were investigated by Yu et al. [78], who found that fucoxanthin induced cell cycle arrest in G2/M phase and apoptosis of MGC-803 cells, and down-regulated the expressions of CyclinB1 and survivin in MGC-803 cells. The study also showed that fucoxanthin might reduce CyclinB1 expression through JAK/STAT signal pathway, and thus inhibit proliferation of MGC-803 cells.

Bladder cancer is not only a serious malignancy but also the most expensive cancer to survey and treat. Zhang et al. [17] showed that fucoxanthin exhibited remarkable antiproliferative effects on human urinary bladder cancer EJ-1 cells and reduced the viability of EJ-1 cells by inducing apoptosis, which was characterized by morphological changes, DNA ladder, and increased percentage of hypodiploid cells, and activating caspase-3 activity with a maximum ratio of apoptotic cells of >93% with 20 μM fucoxanthin.

Primary effusion lymphoma is a very aggressive type of non-Hodgkin’s lymphoma infected by human herpesvirus 8. It was found that fucoxanthin and fucoxanthinol decreased cell viability in primary effusion lymphoma BCBL-1 and TY-1 cells. Fucoxanthin and fucoxanthinol induced cell cycle arrest during G1 phase and caspase-dependent apoptosis, inhibited the activation of nuclear factor-κB, activator protein-1, and phosphatidylinositol 3-kinase/Akt pathways, and down-regulated anti-apoptotic proteins and cell cycle regulators in primary effusion lymphoma cells. In addition, fucoxanthin reduced the growth of primary effusion lymphoma cells in the xenografted mice, suggesting that fucoxanthin could be potentially effective for the treatment of primary effusion lymphoma [54].

An earlier study indicated that fucoxanthin inhibitd the growth of the human neuroblastoma GOTO cells by causing the arrest in the G0–G1 phase of cell cycle and decreasing N-myc gene expression [79]. Subsequently, Nishino et al. [48] found that halocynthiaxanthin showed a more potent inhibitory effect on the growth of human neuroblastoma GOTO cells, and also inhibited the growth of other human malignant tumor cells.

The antiproliferative effect of fucoxanthin is dependent on its isomeric structure. Nakazawa et al. [31] found that the antiproliferative activity of 13-cis and 13′-cis fucoxanthin was significantly higher than that of the all-trans or 9′-cis isomeric forms on the growth of cancer cells. In addition, 13′-cis fucoxanthin had greatest inhibitory effect on the growth of HL-60 cells, followed by 13-cis isomer and all-trans or 9′-cis isomers. It was suggested that the stronger antiproliferative and inhibitory effect of cis-fucoxanthin might be due to the steric hindrances offered by their structure.

In animal experiment, fucoxanthin significantly inhibited the formation and development of aberrant crypt foci, a preneoplastic marker for colon cancer, induced by azoxymethane [80] and 1,2-dimethylhydrazine dihydrochloride [81] in mice. Fucoxanthin had been proven to suppress spontaneous liver tumorigenesis in C3H/He male mice and showed antitumor-promoting activity in a two-stage carcinogenesis experiment in the skin of ICR mice, initiated with 7,12-dimethylbenz[a]anthracene and promoted with 12-O-teradecanoylphorbol-13-acetate and mezerein [13]. In addition, fucoxanthin was reported to inhibit duodenal carcinogenesis induced by N-ethyl-N′-nitro-N-nitrosoguanidine in mice [82].

Although the antitumor effects of fucoxanthin are known, the precise mechanism of action has yet to be elucidated [76]. The anticancer activity of fucoxanthin was partly based on the regulative effect of fucoxanthin on biomolecules related to cell cycle and apoptosis [83]. In addition, fucoxanthin was found to be able to selectively inhibit the mammalian DNA polymerase activities, especially replicative DNA polymerases (i.e., pol α, δ, and ɛ), and thus had anti-neoplastic activity [20]. Further investigations are needed to assess the details of the molecular mechanisms of fucoxanthin against different types of cancer cells with animal models [83].

3.4. Anti-Obese Effect

An excessive accumulation of fat in the body and white adipose tissue causes obesity and a disturbance of cytokine secretion from adipose tissue, and thus results in an increased risk of many serious diseases such as type II diabetes, hyperlipidemia, hypertension, and cardiovascular disease [26,50,84].

Maeda et al. [26] firstly reported that lipids from U. pinnatifida reduced abdominal white adipose tissue weights in Wistar rats and KK-Ay mice. Miyata et al. [18] showed that L. japonica and L. ochotensis inhibited fat absorption, decreased the serum triglyceride level in SD rats, and had an anti-obesity effect on ddY mice induced by a high-fat diet. It was suggested that fucoxanthin was an active component for the antiobesity effect [26]. Many studies have shown that fucoxanthin, even with a 0.02% dose [85], significantly lowered body weight [43,8688], body fat accumulation [89], visceral fat-pads weights [85,87], white adipose tissue weight gain [50,8890], and the size of adipocyte [85] in diabetic/obese KK-Ay mice, high-fat diet-induced obese C57BL/6N mice or C57BL/6J mice, and increased brown adipose tissue weight in KK-Ay mice [50]. However, fucoxanthin did not affect white adipose tissue weight gain in lean C57BL/6J mice [90]. It was found that fucoxanthin significantly reduced plasma and hepatic triglyceride concentrations and the activities of adipocytic fatty acid synthesis, hepatic fatty acid and triglyceride synthesis, and cholesterol-regulating enzymes, and significantly increased the concentrations of plasma high-density lipoprotein-cholesterol, fecal triglyceride and cholesterol, as well as fatty acid oxidation enzyme activity in epididymal white adipose tissue of mice, indicating that fucoxanthin ameliorated the plasma and hepatic lipid profile, fecal lipids and body fat mass, hepatic cholesterol metabolism, fatty acid synthesis, and lipid absorption [57,88]. Moreover, fucoxanthin significantly lowered mRNA expression of proliferators activated receptor γ and the activity of hepatic phosphatidate phosphohydrolase, and significantly increased the mRNA expressions of β-oxidation-related acyl-coA oxidase 1, palmitoyl and proliferators activated receptor α [57]. In addition, fucoxanthin and fucoxanthinol inhibited both lymphatic triglyceride absorption and the increase of triglyceride concentration in systemic blood, likely due to their inhibitory effects on lipase activity in the gastrointestinal lumen [91].

The potential anti-obesity effect might be mediated by improving plasma adipokine level (e.g., lowered leptin level and elevated adiponectin level), down-regulating various lipogenic enzyme activities and fat production, up-regulating fatty acid β-oxidation activity and uncoupling protein gene expressions in visceral adipose tissues, suggesting that fucoxanthin might act as a regulator of lipid metabolism in fat tissues [87]. Mitochondrial uncoupling protein 1, usually expressed only in brown adipose tissue that occurs little in adult humans, is a key molecule for metabolic thermogenesis to avoid an excess of fat accumulation [26]. Many studies suggested that the antiobesity effect of fucoxanthin was due to oxidation of fatty acids, heat production, and energy dissipation through upregulating the expression of uncoupling protein 1 in the white adipose tissue [26,50,51,86,88,92], and thus inducing the decrease in abdominal fat in mice [86]. Recently, Miyashita et al. [83] reported that fucoxanthin promoted mRNA expression of β3-adrenergic receptor in white adipose tissue of obese mice, which was responsible for lipolysis and thermogenesis. The regulatory effect of fucoxanthin on peroxisome proliferator-activated receptor γ expression in adipose tissue was an important modulator for uncoupling protein 1 expression. Leptin is mainly produced in adipocyte and controls body weight and fat weight by regulating the food intake and energy expenditure. Fucoxanthin remarkably reduced leptin mRNA in white adipose tissue and the level of plasma leptin in KK-Ay mice [50] and high fat diet-induced obese C57BL/6J mice [85,89]. The lower leptin level might reflect the decrease in the size of white adipose tissue induced by fucoxanthin [50]. In addition, Sugawara et al. [93] found that fucoxanthin had significant antiangiogenic activity, which was also responsible for its anti-obesity effect.

Maeda et al. [84] showed that fucoxanthin and fucoxanthinol inhibited intercellular lipid accumulation and decreased glycerol-3-phosphate dehydrogenase activity during adipocyte differentiation of 3T3-L1 cells. The suppressive effect of fucoxanthinol on the differentiation of murine 3T3-L1 preadipocytes to adipocytes was stronger than that of fucoxanthin [84], and the suppressive effect of amarouciaxanthin A, a dominant metabolite of fucoxanthin in white adipose tissue, was stronger than that of fucoxanthinol [94]. Amarouciaxanthin A markedly down-regulated the mRNA expressions of adipocyte fatty acid-binding protein, lipoprotein lipase, and glucose-transporter 4 in 3T3-L1 cells [94]. Kang et al. [95] found that that fucoxanthin inhibited 3T3-L1 adipocyte differentiation at intermediate (days 2–4) and late stages (days 4–7), whereas it enhanced 3T3-L1 adipocyte differentiation at an early stage (days 0–2) by modulating the expression of key adipogenic transcriptional regulators such as peroxisome proliferator-activated receptor γ, CCAAT/enhancer-binding protein α, and sterol regulatory element-binding protein 1c, and inhibited glucose uptake by suppressing the phosphorylation of insulin receptor substrate 1 in mature 3T3-L1 adipocytes, suggesting that fucoxanthin exerted anti-obesity effect by inhibiting the expression of key transcriptional regulators at intermediate and late stages and glucose uptake in mature adipocytes. Noticeably, some non-allenic carotenoids, such as lutein, lutein epoxide, α-carotene, and β-carotene 5,6-epoxide, were found to not exhibit the suppressive effect on adipocyte differentiation in 3T3-L1 cells, indicating that the allene bond of fucoxanthin and its metabolites might be important for the inhibition [83,92,94,96].

Maeda et al. showed that, although no significant uncoupling protein 1 expression in the white adipose tissue of KK-Ay mice fed fish oil [50] or medium-chain triacylglycerols [51] was found, the anti-obesity effect of fucoxanthin was increased by dissolving fucoxanthin in fish oil or medium-chain triacylglycerols, indicating the combination of fucoxanthin and lipids is more effective for attenuating the weight gain of the white adipose tissue than feeding with fucoxanthin alone, and suggesting that the presence of lipids can increase the absorption rate of fucoxanthin in KK-Ay mice [50,51]. Recently, Okada et al. [32] developed a lipid delivery system, and suggested that incorporation of U. pinnatifida lipid into phospholipid by means of capsulation might lead to an additive increase in the antiobesity effect of fucoxanthin on KK-Ay mice.

In a 16-week clinical trial, Abidov et al. [52] investigated the effects of orally administered the mixture (Xanthigen) of fucoxanthin and pomegranate seed oil on body weight, body fat, liver lipids, blood biochemistry, and resting energy expenditure in obese, non-diabetic premenopausal women diagnosed with non-alcoholic fatty liver disease or presenting with normal liver fat. The results showed that Xanthigen reduced body weight (from 94.1 ± 2.1 and 94.5 ± 2.1 to 87.2 ± 3.7 and 88.2 ± 1.9 kg for volunteers with fatty liver and normal liver, respectively), body fat (from 42.3 ± 2.2 and 43.3 ± 2.9 to 37.9 ± 2.9 and 38.1 ± 3.2 kg, respectively), and liver fat content (from 15.3 ± 4.1 and 5.1 ± 1.5 to 9.4 ± 3.1 and 3.4 ± 1.8%, respectively), improved liver function tests in obese non-diabetic women, and increased resting energy expenditure.

3.5. Antidiabetic Activity

Maeda et al. [50] found that fucoxanthin markedly decreased the blood glucose and plasma insulin levels, as well as water intake in diabetic/obese KK-Ay mice. It was suggested that fucoxanthin improved insulin resistance and decreased blood glucose level, at least in part, through downregulating adipokines such as tumor necrosis factor-α, monocyte chemoattractant protein-1, interleukin-6, and plasminogen activator inhibitor-1 via downregulating their mRNA expression by directly acting on adipocytes and macrophages in white adipose tissue and up-regulation of glucose transporter 4 in skeletal muscle in KK-Ay mice [50,83,89,90,92].

Hosokawa et al. [90] demonstrated that fucoxanthin attenuated hyperglycemia in KK-Ay mice, but did not affect blood glucose levels in lean C57BL/6J mice. However, a high-fat feeding could prompt obesity, hyperinsulinemia, high blood glucose, insulin resistance, and non-alcoholic fatty liver disease in C57BL/6J mice [85]. Maeda et al. [89] and Park et al. [85] showed that fucoxanthin significantly lowered the fasting blood glucose concentration, the plasma insulin level, and the insulin resistance index in diet-induced obese mice. Fucoxanthin might improve altera–tions in lipid metabolism and insulin resistance induced by a high fat diet, at least in part, through reducing visceral fat mass, hyperinsulinemia, hepatic glucose production, and hepatic lipogenesis, and altering hepatic glucose-regulating enzymes activities [85]. Moreover, Woo et al. [57] demonstrated that fucoxanthin significantly reduced the blood glucose, hemoglobin A1c, plasma insulin, and resistin levels, and no change was found in the plasma glucagon concentration in high-fat diet fed C57BL/6N mice, indicating that the reduction in the insulin/glucagon ratio could be in part responsible to lowering blood glucose concentration by fucoxanthin.

3.6. Hepatoprotective Effect

Woo et al. [57] found that fucoxanthin significantly lowered the hepatic lipid contents, while feces weight and fecal lipids significantly increased by inhibiting lipid adsorption in high-fat diet fed C57BL/6N mice. Park et al. [85] also demonstrated that fucoxanthin significantly decreased the hepatic lipid droplet accumulation in high-fat fed mice, possibly through reducing the activity of hepatic fatty acid synthesis-related enzymes [57,85]. Furthermore, it was shown that there were no significant dose-dependent effects on hepatic lipid changes by 0.05% and 0.2% fucoxanthin and the 0.05% fucoxanthin might be sufficient for improving the hepatic lipid content [57], while no significant change was found in the plasma lipids in Wister rats [86]. In addition, fucoxanthin significantly up-regulated glycolytic enzyme such as glucokinase in the liver, and thus increased the ratio of hepatic glucokinase/glucose-6-phosphatase and glycogen content, indicating that fucoxanthin normalized the hepatic glycogen content in high-fat fed mice [85].

The reduction of liver lipids might be due to the increase of docosahexaenoic acid, which reduces the activity of hepatic enzymes in fatty acid synthesis and increases hepatic fatty acid β-oxidation, in the liver [86]. Tsukui et al. [97] first reported that fucoxanthin and fucoxanthinol enhanced the amount of docosahexaenoic acid in the liver of KK-Ay mice, whereas the level of docosahexaenoic acid in the small intestine remained unaltered. Subsequently, Tsukui et al. [43] confirmed that fucoxanthin increased the amount of docosahexaenoic acid in the liver of normal adult C57BL/6J mice. In addition, an increase in arachidonic acid (ω-6) was also found in fucoxanthin-fed mice, indicating that fucoxanthin might modify the metabolic pathways of ω-3 and ω-6 highly unsaturated fatty acids. Recently, Airanthi et al. [10] showed that the levels of docosahexaenoic acid and arachidonic acid in liver lipids of KK-Ay mice given the lipids from brown seaweeds significantly increased.

Furthermore, Liu et al. [98] investigated the effects of fucoxanthin on hepatocyte lipid peroxidation and hepatotoxicity induced by ferric nitrilotriacetate in murine embryonic hepatic BNL CL.2 cells, and showed that fucoxanthin significantly recovered cell proliferation and increased the levels of glutathione. Moreover, fucoxanthin significantly decreased intracellular reactive oxygen species and DNA damage, and markedly decreased the level of thiobarbituric acid-reactive substances and protein carbonyl contents in BNL CL.2 cells induced by ferric nitrilotriacetate, indicating that fucoxanthin effectively protected against ferric nitrilotriacetate-induced hepatotoxicity by decreasing intracellular reactive oxygen species, thiobarbituric acid-reactive substances, and protein carbonyl contents, and increasing glutathione level, associated with the antioxidant effects of fucoxanthin.

3.7. Skin-Protective Effect

Over exposure to ultraviolet radiation from sunlight leading to the generation of reactive oxygen species, inflammatory reaction, and angiogenesis of the skin is presumed to be the primary causative agent in the damage of cellular constituents and some cutaneous disease such as pigmentation, laxity, wrinkling, erythema, and skin carcer [99,100]. Heo and Jeon [99] revealed that fucoxanthin significantly decreased intracellular reactive oxygen species generated by exposure to ultraviolet B radiation in human fibroblast. Fucoxanthin elevated cell survival rate and inhibited cell damage for pre-treated cells, indicating that fucoxanthin could protect skin against photodamage induced by ultraviolet B irradiation from sunlight. Shimoda et al. [101] found that fucoxanthin inhibited tyrosinase activity, melanogenesis in melanoma, and ultraviolet B-induced skin pigmentation. The results showed that fucoxanthin significantly suppressed expression of cyclooxygenase-2, endothelin receptor A, p75 neurotrophin receptor, prostaglandin E receptor 1, melanocortin 1 receptor and tyrosinase-related protein 1, suggesting that fucoxanthin presented anti-pigmentary activity by topical or oral application in ultraviolet B-induced melanogenesis possibly through the suppression of prostaglandin E2 synthesis and melanogenic stimulant receptors. Recently, Urikura et al. [100] showed that fucoxanthin significantly suppressed ultraviolet B-induced epidermal hypertrophy, which may cause wrinkle formation, vascular endothelial growth factor, matrix metalloproteinases-13 expression, and the increase of thiobarbituric acid reactive substances in the skin of hairless mice. The results indicated that topical treatment with fucoxanthin prevented skin photoage and wrinkle formation in ultraviolet B-irradiated hairless mice, possibly through the antioxidant and antiangiogenic effects of fucoxanthin. These studies suggest that fucoxanthin may be an effective ultraviolet protcect ingredient able to be used in cosmetic and sunscreen in protecting skin from photoaging. Moreover, it would be worthy to probe into the effect of oral administration of fucoxanthin on skin photoage.

3.8. Antiangiogenic Effect

Sugawara et al. [93] investigated the antiangiogenic effects of fucoxanthin using cultured human umbilical vein endothelial cells and the rat aortic ring, and found that fucoxanthin could significantly suppress the differentiation of endothelial progenitor cells into endothelial cells and the formation of new blood vessels, and significantly reduced the tube length of endothelial cells. The results showed that fucoxanthin and fucoxanthinol inhibited microvessel outgrowth in an ex vivo angiogenesis assay using a rat aortic ring, suggesting that the antiangiogenic effect of fucoxanthin might be useful in preventing angiogenesis-related diseases, such as cancer, diabetic retinopathy, atherosclerosis and psoriasis.

3.9. Cerebrovascular Protective Effect

Ikeda et al. [24] revealed that the brown seaweed U. pinnatifida significantly delayed the development of stroke signs with no change in blood pressure and increased the life span of salt-loaded hypertensive rats. In addition, the preventive effect of fucoxanthin on cultured neuronal cells from hypertensive rats was also investigated by Ikeda et al. [24], who found that fucoxanthin markedly attenuated neuronal cell injury in hypoxia and re-oxygenation, possibly through its radical-scavenging activity, and suggested that fucoxanthin had a beneficial effect on cerebrovascular diseases against ischaemic neuronal cell death in stroke-prone spontaneously hypertensive rats.

3.10. Bone-Protective Effect

Using cells from the macrophage cell line RAW264.7 able to differentiate into osteoclast-like cells when stimulated by receptor activator of nuclear factor κB ligand, Das et al. [41] investigated the effects of fucoxanthin on the osteoclast differentiation of precursor RAW264.7 monocytes and its cytotoxicity against the osteoclast-like cells differentiated from RAW264.7 cells and the osteoblast-like cell line MC3T3-E1 cells. The results showed that fucoxanthin significantly suppressed the differentiation of RAW264.7 cells with no toxicity to RAW264.7 cells, induced apoptosis through the activation of caspase-3 and sequentially the cleavage of poly-ADP-ribose polymerase in osteoclast-like cells, and did not decrease cell viability in the osteoblast-like cell line MC3T3-E1, indicating that the cytotoxicity of fucoxanthin against osteoclasts was stronger than that against osteoblasts. The study suggested that fucoxanthin suppressed osteoclastogenesis through inhibiting osteoclast differentiation and inducing apoptosis in osteoclasts, but did not antagonize bone formation, and fucoxanthinol might play an important role in inducing apoptosis in osteoclast-like cells and exert a suppressive effect on osteoclastogenesis. These results indicate that fucoxanthin is helpful for the prevention of bone diseases such as osteoporosis and rheumatoid arthritis.

3.11. Ocular Protective Effect

After-cataract, also known as posterior capsule opacification, is the main long term complication of extracapsular cataract extraction due to the proliferation and migration of lens epithelial cells left in the capsular bag after cataract surgery [102]. The growth of human lens epithelial cell line SRA 01/04 was apparently inhibited by fucoxanthin, indicating that fucoxanthin was an efficient and safe antiproliferative agent for human lens epithelial cell line and might be applied to the formulation of ocular implant products used in cataract treatment for the prevention of after-cataract [36].

In addition, Shiratori et al. [103] studied the anti-ocular inflammatory effect of fucoxanthin on lipopolysaccharide-induced uveitis in male Lewis rats, and found that fucoxanthin suppressed the development of the uveitis.

3.12. Antimalarial Effect

Malaria, widespread in tropical and subtropical regions, is a mosquito-borne infectious disease of humans caused by Plasmodium falciparum, a one-celled apicomplexan parasite. Afolayan et al. [21] first found that organic extract from brown seaweed S. heterophyllum exhibited promising antiplasmodial activity, and thus separated sargaquinoic acid, sargahydroquinoic acid, sargaquinal, and fucoxanthin from the extract for further investigation. The results indicated that fucoxanthin showed the highest antiplasmodial activity, while sargaquinal showed good antiplasmodial activity, and sargaquinoic acid and sargahydroquinoic acid were only moderately active. Although the antiplasmodial activities of four compounds might be related to their antioxidant properties, further studies were required in order to clarify their mode of action.

4. Conclusions

Growing evidence from tissue culture and animal experiment suggests that fucoxanthin has potential health promoting effects. Fucoxanthin has attracted considerable interest because of its potent bioactivities, including its antioxidant, anti-inflammatory, anticancer, anti-obese, antidiabetic, antiangiogenic, and antimalarial activities, and its protective effects on the liver, blood vessels of the brain, bones, skin, and eyes. Particularly, the anti-obese effect, antiproliferative effects on adult T-cell leukemia cells [53], and inhibitory effect on the viability of HL-60 cells [73] of fucoxanthin are distinctly more potent than that of β-carotene and astaxanthin. The unique suppressive effect of fucoxanthin on adipocyte differentiation is related to its structural properties, where an allenic bond is essential for the expression of this activity, and carotenoids without an allenic bond are not active [83].

Orally-administered fucoxanthin is metabolized into fucoxanthinol and amarouciaxanthin A in mice. Therefore, fucoxanthinol, amarouciaxanthin A, or other metabolites of fucoxanthin in human should be considered in mechanistic studies of the biological actions of fucoxanthin. Although some brown seaweeds containing high levels of fucoxanthin are the most common edible delicacies, some studies showed that the bioavailability of fucoxanthin in brown seaweeds was low in humans. However, dietary combination of fucoxanthin isolated from brown seaweeds or diatoms and edible oil or lipid could increase the absorption rate of fucoxanthin, and might be developed as a promising marine drug. More extensive animal experimentation and well-controlled clinical trials are suggested for further studies.


  1. Dembitsky, VM; Maoka, T. Allenic and cumulenic lipids. Prog. Lipid Res 2007, 46, 328–375. [Google Scholar]
  2. Nomura, T; Kikuchi, M; Kubodera, A; Kawakami, Y. Proton-donative antioxidant activity of fucoxanthin with 1,1-diphenyl-2-picrylhydrazyl (DPPH). Biochem. Mol. Biol. Int 1997, 42, 361–370. [Google Scholar]
  3. Beppu, F; Niwano, Y; Tsukui, T; Hosokawa, M; Miyashita, K. Single and repeated oral dose toxicity study of fucoxanthin (FX), a marine carotenoid, in mice. J. Toxicol. Sci 2009, 34, 501–510. [Google Scholar]
  4. Willstätter, R; Page, HJ. Chlorophyll. XXIV. The pigments of the brown algae. Justus Liebigs Ann. Chem 1914, 404, 237–271. [Google Scholar]
  5. Englert, G; Bjørnland, T; Liaaen-Jensen, S. 1D and 2D NMR study of some allenic carotenoids of the fucoxanthin series. Magn Reson Chem 1990, 28, 519–528. [Google Scholar]
  6. Sangeetha, RK; Bhaskar, N; Divakar, S; Baskaran, V. Bioavailability and metabolism of fucoxanthin in rats: structural characterization of metabolites by LC-MS (APCI). Mol. Cell. Biochem 2010, 333, 299–310. [Google Scholar]
  7. Bertrand, M. Carotenoid biosynthesis in diatoms. Photosynth. Res 2010, 106, 89–102. [Google Scholar]
  8. Airanthi, MWA; Hosokawa, M; Miyashita, K. Comparative antioxidant activity of edible Japanese brown seaweeds. J. Food Sci 2011, 76, C104–C111. [Google Scholar]
  9. Mise, T; Ueda, M; Yasumoto, T. Production of fucoxanthin-rich powder from Cladosiphon okamuranus. Adv. J. Food Sci. Technol 2011, 3, 73–76. [Google Scholar]
  10. Airanthi, MKWA; Sasaki, N; Iwasaki, S; Baba, N; Abe, M; Hosokawa, M; Miyashita, K. Effect of brown seaweed lipids on fatty acid composition and lipid hydroperoxide levels of mouse liver. J. Agric. Food Chem 2011, 59, 4156–4163. [Google Scholar]
  11. Strand, A; Herstad, O; Liaaen-Jensen, S. Fucoxanthin metabolites in egg yolks of laying hens. Comp. Biochem. Phys. A Mol. Integr. Physiol 1998, 119, 963–974. [Google Scholar]
  12. Zaragozá, MC; López, D; Sáiz, MP; Poquet, M; Pérez, J; Puig-Parellada, P; Mármol, F; Simonetti, P; Gardana, C; Lerat, Y; Burtin, P; Inisan, C; Rousseau, I; Besnard, M; Mitjavila, MT. Toxicity and antioxidant activity in vitro and in vivo of two Fucus vesiculosus extracts. J. Agric. Food Chem 2008, 56, 7773–7780. [Google Scholar]
  13. Nishino, H. Cancer prevention by carotenoids. Mutat. Res 1998, 402, 159–163. [Google Scholar]
  14. Yan, X; Chuda, Y; Suzuki, M; Nagata, T. Fucoxanthin as the major antioxidant in Hijikia fusiformis, a common edible seaweed. Biosci. Biotechnol. Biochem 1999, 63, 605–607. [Google Scholar]
  15. Kim, KN; Heo, SJ; Kang, SM; Ahn, G; Jeon, YJ. Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROS-mediated Bcl-xL pathway. Toxicol. Vitro 2010, 24, 1648–1654. [Google Scholar]
  16. Das, SK; Hashimoto, T; Kanazawa, K. Growth inhibition of human hepatic carcinoma HepG2 cells by fucoxanthin is associated with down-regulation of cyclin D. Biochim. Biophys. Acta 2008, 1780, 743–749. [Google Scholar]
  17. Zhang, ZY; Zhang, PJ; Hamada, M; Takahashi, S; Xing, GQ; Liu, JQ; Sugiura, N. Potential chemoprevention effect of dietary fucoxanthin on urinary bladder cancer EJ-1 cell line. Oncol. Rep 2008, 20, 1099–1103. [Google Scholar]
  18. Miyata, M; Koyama, T; Kamitani, T; Toda, T; Yazawa, K. Anti-obesity effect on rodents of the traditional Japanese food, tororokombu, shaved Laminaria. Biosci. Biotechnol. Biochem 2009, 73, 2326–2328. [Google Scholar]
  19. Heo, SJ; Yoon, WJ; Kim, KN; Ahn, GN; Kang, SM; Kang, DH; Affan, A; Oh, C; Jung, WK; Jeon, YJ. Evaluation of anti-inflammatory effect of fucoxanthin isolated from brown algae in lipopolysaccharide-stimulated RAW 264.7 macrophages. Food Chem. Toxicol 2010, 48, 2045–2051. [Google Scholar]
  20. Murakami, C; Takemura, M; Sugiyama, Y; Kamisuki, S; Asahara, H; Kawasaki, M; Ishidoh, T; Linn, S; Yoshida, S; Sugawara, F; Yoshida, H; Sakaguchi, K; Mizushina, Y. Vitamin A-related compounds, all-trans retinal and retinoic acids, selectively inhibit activities of mammalian replicative DNA polymerases. Biochim. Biophys. Acta 2002, 1574, 85–92. [Google Scholar]
  21. Afolayan, AF; Bolton, JJ; Lategan, CA; Smith, PJ; Beukes, DR. Fucoxanthin, tetraprenylated toluquinone and toluhydroquinone metabolites from Sargassum heterophyllum inhibit the in vitro growth of the malaria parasite Plasmodium falciparum. Z. Naturforsch. C 2008, 63, 848–852. [Google Scholar]
  22. Heo, SJ; Ko, SC; Kang, SM; Kang, HS; Kang, HS; Kim, JP; Kim, SH; Lee, KW; Cho, MG; Jeon, YJ. Cytoprotective effect of fucoxanthin isolated from brown algae Sargassum siliquastrum against H2O2-induced cell damage. Eur. Food Res. Technol 2008, 228, 145–151. [Google Scholar]
  23. Hosokawa, M; Wanezaki, S; Miyauchi, K; Kurihara, H; Kohno, H; Kawabata, J; Kawabata, J; Odashima, S; Takahashi, K. Apoptosis-inducing effect of fucoxanthin on human leukemia cell line HL-60. Food Sci. Technol. Res 1999, 5, 243–246. [Google Scholar]
  24. Ikeda, K; Kitamura, A; Machida, H; Watanabe, M; Negishi, H; Hiraoka, J; Nakano, T. Effect of Undaria pinnatifida (wakame) on the development of cerebrovascular diseases in stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol 2003, 30, 44–48. [Google Scholar]
  25. Hosokawa, M; Kudo, M; Maeda, H; Kohno, H; Tanaka, T; Miyashita, K. Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARγ ligand, troglitazone, on colon cancer cells. Biochim. Biophys. Acta 2004, 1675, 113–119. [Google Scholar]
  26. Maeda, H; Hosokawa, M; Sashima, T; Funayama, K; Miyashita, K. Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem. Biophys. Res. Commun 2005, 332, 392–397. [Google Scholar]
  27. Sachindra, NM; Sato, E; Maeda, H; Hosokawa, M; Niwano, Y; Kohno, M; Miyashita, K. Radical scavenging and singlet oxygen quenching activity of marine carotenoid fucoxanthin and its metabolites. J. Agric. Food Chem 2007, 55, 8516–8522. [Google Scholar]
  28. Asai, A; Yonekura, L; Nagao, A. Low bioavailability of dietary epoxyxanthophylls in humans. Br. J. Nutr 2008, 100, 273–277. [Google Scholar]
  29. Khan, MNA; Lee, MC; Kang, JY; Park, NG; Fujii, H; Hong, YK. Effects of the brown seaweed Undaria pinnatifida on erythematous inflammation assessed using digital photo analysis. Phytother. Res 2008, 22, 634–639. [Google Scholar]
  30. Liu, CL; Huang, YS; Hosokawa, M; Miyashita, K; Hu, ML. Inhibition of proliferation of a hepatoma cell line by fucoxanthin in relation to cell cycle arrest and enhanced gap junctional intercellular communication. Chem. Biol. Interact 2009, 182, 165–172. [Google Scholar]
  31. Nakazawa, Y; Sashima, T; Hosokawa, M; Miyashita, K. Comparative evaluation of growth inhibitory effect of stereoisomers of fucoxanthin in human cancer cell lines. J. Funct. Foods 2009, 1, 88–97. [Google Scholar]
  32. Okada, T; Mizuno, Y; Sibayama, S; Hosokawa, M; Miyashita, K. Antiobesity effects of Undaria lipid capsules prepared with scallop phospholipids. J. Food Sci 2011, 76, H2–H6. [Google Scholar]
  33. Iio, K; Okada, Y; Ishikura, M. Single and 13-week oral toxicity study of fucoxanthin oil from microalgae in rats. J. Food Hyg. Soc. Jpn 2011, 52, 183–189. [Google Scholar]
  34. Iio, K; Okada, Y; Ishikura, M. Bacterial reverse mutation test and micronucleus test of fucoxanthin oil from microalgae. Shokuhin Eiseigaku Zasshi 2011, 52, 190–193. [Google Scholar]
  35. Rijstenbil, JW. Effects of UVB radiation and salt stress on growth, pigments and antioxidative defence of the marine diatom Cylindrotheca closterium. Mar. Ecol. Prog. Ser 2003, 254, 37–48. [Google Scholar]
  36. Moreau, D; Tomasoni, C; Jacquot, C; Kaas, R; Le Guedes, R; Cadoret, JP; Muller-Feuga, A; Kontiza, I; Vagias, C; Roussis, V; Roussakis, C. Cultivated microalgae and the carotenoid fucoxanthin from Odontella aurita as potent anti-proliferative agents in bronchopulmonary and epithelial cell lines. Environ. Toxicol. Pharmcol 2006, 22, 97–103. [Google Scholar]
  37. Sugawara, T; Kushiro, M; Zhang, H; Nara, E; Ono, H; Nagao, A. Lysophosphatidylcholine enhances carotenoid uptake from mixed micelles by Caco-2 human intestinal cells. J. Nutr 2001, 131, 2921–2927. [Google Scholar]
  38. Yonekura, L; Kobayashi, M; Terasaki, M; Nagao, A. Keto-carotenoids are the major metabolites of dietary lutein and fucoxanthin in mouse tissues. J. Nutr 2010, 140, 1824–1831. [Google Scholar]
  39. Hashimoto, T; Ozaki, Y; Taminato, M; Das, SK; Mizuno, M; Yoshimura, K; Maoka, T; Kanazawa, K. The distribution and accumulation of fucoxanthin and its metabolites after oral administration in mice. Br. J. Nutr 2009, 102, 242–248. [Google Scholar]
  40. Sugawara, T; Baskaran, V; Tsuzuki, W; Nagao, A. Brown algae fucoxanthin is hydrolyzed to fucoxanthinol during absorption by Caco-2 human intestinal cells and mice. J. Nutr 2002, 132, 946–951. [Google Scholar]
  41. Das, SK; Ren, RD; Hashimoto, T; Kanazawa, K. Fucoxanthin induces apoptosis in osteoclast-like cells differentiated from RAW264.7 cells. J. Agric. Food Chem 2010, 58, 6090–6095. [Google Scholar]
  42. Asai, A; Sugawara, T; Ono, H; Nagao, A. Biotransformation of fucoxanthinol into amarouciaxanthin A in mice and HepG2 cells: formation and cytotoxicity of fucoxanthin metabolites. Drug Metab. Dispos 2004, 32, 205–211. [Google Scholar]
  43. Tsukui, T; Baba, N; Hosokawa, M; Sashima, T; Miyashita, K. Enhancement of hepatic docosahexaenoic acid and arachidonic acid contents in C57BL/6J mice by dietary fucoxanthin. Fish. Sci 2009, 75, 261–263. [Google Scholar]
  44. Sangeetha, RK; Bhaskar, N; Baskaran, V. Comparative effects of β-carotene and fucoxanthin on retinol deficiency induced oxidative stress in rats. Mol. Cell. Biochem 2009, 331, 59–67. [Google Scholar]
  45. Murakami, A; Nakashima, M; Koshiba, T; Maoka, T; Nishino, H; Yano, M; Sumida, T; Kim, OK; Koshimizu, K; Ohigashi, H. Modifying effects of carotenoids on superoxide and nitric oxide generation from stimulated leucocytes. Cancer Lett 2000, 149, 115–123. [Google Scholar]
  46. Maoka, T. Carotenoids in marine animals. Mar. Drugs 2011, 9, 278–293. [Google Scholar]
  47. Maoka, T; Fujiwara, Y; Hashimoto, K; Akimoto, N. Carotenoids in three species of corbicula clams, Corbicula japonica, Corbicula sandai, and Corbicula sp. (Chinese freshwater corbicula clam). J. Agric. Food Chem 2005, 53, 8357–8364. [Google Scholar]
  48. Nishino, H; Tsushima, M; Matsuno, T; Tanaka, Y; Okuzumi, J; Murakoshi, M; Satomi, Y; Takayasu, J; Tokuda, H; Nishino, A. Anti-neoplastic effect of halocynthiaxanthin, a metabolite of fucoxanthin. Anticancer Drugs 1992, 3, 493–497. [Google Scholar]
  49. Konishi, I; Hosokawa, M; Sashima, T; Kobayashi, H; Miyashita, K. Halocynthiaxanthin and fucoxanthinol isolated from Halocynthia roretzi induce apoptosis in human leukemia, breast and colon cancer cells. Comp. Biochem. Phys. C 2006, 142, 53–59. [Google Scholar]
  50. Maeda, H; Hosokawa, M; Sashima, T; Miyashita, K. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. J. Agric. Food Chem 2007, 55, 7701–7706. [Google Scholar]
  51. Maeda, H; Hosokawa, M; Sashima, T; Funayama, K; Miyashita, K. Effect of medium-chain triacylglycerols on anti-obesity effect of fucoxanthin. J. Oleo Sci 2007, 56, 615–621. [Google Scholar]
  52. Abidov, M; Ramazanov, Z; Seifulla, R; Grachev, S. The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes Obes. Metab 2010, 12, 72–81. [Google Scholar]
  53. Ishikawa, C; Tafuku, S; Kadekaru, T; Sawada, S; Tomita, M; Okudaira, T; Nakazato, T; Toda, T; Uchihara, JN; Taira, N; Ohshiro, K; Yasumoto, T; Ohta, T; Mori, N. Antiadult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product fucoxanthinol. Int. J. Cancer 2008, 123, 2702–2712. [Google Scholar]
  54. Yamamoto, K; Ishikawa, C; Katano, H; Yasumoto, T; Mori, N. Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas. Cancer Lett 2011, 300, 225–234. [Google Scholar]
  55. Kadekaru, T; Toyama, H; Yasumoto, T. Safety evaluation of fucoxanthin purified from Undaria pinnatifida. J. Jpn. Soc. Food Sci 2008, 55, 304–308. [Google Scholar]
  56. Beppu, F; Niwano, Y; Sato, E; Kohno, M; Tsukui, T; Hosokawa, M; Miyashita, K. In vitro and in vivo evaluation of mutagenicity of fucoxanthin (FX) and its metabolite fucoxanthinol (FXOH). J. Toxicol. Sci 2009, 34, 693–698. [Google Scholar]
  57. Woo, MN; Jeon, SM; Kim, HJ; Lee, MK; Shin, SK; Shin, YC; Park, YB; Choi, MS. Fucoxanthin supplementation improves plasma and hepatic lipid metabolism and blood glucose concentration in high-fat fed C57BL/6N mice. Chem. Biol. Interact 2010, 186, 316–322. [Google Scholar]
  58. Burton, GW; Ingold, KU. β-Carotene: an unusual type of lipid antioxidant. Science 1984, 224, 569–573. [Google Scholar]
  59. Le Tutour, B; Benslimane, F; Gouleau, MP; Gouygou, JP; Saadan, B; Quemeneur, F. Antioxidant and prooxidant activities of the brown algae, Laminaria digitata, Himanthalia elongata, Fucus vesiculosus, Fucus serratus and Ascophyllum nodosum. J. Appl. Phycol 1998, 10, 121–129. [Google Scholar]
  60. Sangeetha, RK; Bhaskar, N; Baskaran, V. Fucoxanthin restrains oxidative stress induced by retinol deficiency through modulation of Na+K+-ATPase and antioxidant enzyme activities in rats. Eur. J. Nutr 2008, 47, 432–441. [Google Scholar]
  61. Li, TL; King, JM; Min, DB. Quenching mechanisms and kinetics of carotenoids in riboflavin photosensitized singlet oxygen oxidation of vitamin D2. J. Food Biochem 2000, 24, 477–492. [Google Scholar]
  62. Liu, CL; Chiu, YT; Hu, ML. Fucoxanthin enhances HO-1 and NQO1 expression in murine hepatic BNL CL.2 cells through activation of the Nrf2/ARE system partially by its pro-oxidant activity. J Agric Food Chem 2011. [Google Scholar] [CrossRef]
  63. Choi, SK; Park, YS; Choi, DK; Chang, HI. Effects of astaxanthin on the production of NO and the epression of COX-2 and iNOS in LPS-simulated BV2 microglial cells. J. Microbiol. Biotechnol 2008, 18, 1990–1996. [Google Scholar]
  64. Lee, SJ; Bai, SK; Lee, KS; Namkoong, S; Na, HJ; Ha, KS; Han, JA; Yim, SV; Chang, K; Kwon, YG; Lee, SK; Kim, YM. Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol. Cells 2003, 16, 97–105. [Google Scholar]
  65. Kim, KN; Heo, SJ; Yoon, WJ; Kang, SM; Ahn, G; Yi, TH; Jeon, YJ. Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-κB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur. J. Pharmacol 2010, 649, 369–375. [Google Scholar]
  66. Sakai, S; Sugawara, T; Matsubara, K; Hirata, T. Inhibitory effect of carotenoids on the degranulation of mast cells via suppression of antigen-induced aggregation of high affinity IgE receptor. J. Biol. Chem 2009, 284, 28172–28179. [Google Scholar]
  67. Sakai, S; Sugawara, T; Hirata, T. Inhibitory effect of dietary carotenoids on dinitrofluorobenzene-induced contact hypersensitivity in mice. Biosci. Biotechnol. Biochem 2011, 75, 1013–1015. [Google Scholar]
  68. Khan, MNA; Suk-Choi, J; Lee, MC; Kim, E; Nam, TJ; Fujii, H; Hong, YK. Anti-inflammatory activities of methanol extracts from various seaweed species. J. Environ. Biol 2008, 29, 465–469. [Google Scholar]
  69. Khan, MNA; Yoon, SJ; Choi, JS; Park, NG; Lee, HH; Cho, JY; Hong, YK. Anti-edema effects of brown seaweed (Undaria pinnatifida) extract on phorbol 12-myristate 13-acetate-induced mouse ear inflammation. Am. J. Chin. Med 2009, 37, 373–381. [Google Scholar]
  70. Kotake-Nara, E; Kushiro, M; Zhang, H; Sugawara, T; Miyashita, K; Nagao, A. Carotenoids affect proliferation of human prostate cancer cells. J. Nutr 2001, 131, 3303–3306. [Google Scholar]
  71. Kotake-Nara, E; Sugawara, T; Nagao, A. Antiproliferative effect of neoxanthin and fucoxanthin on cultured cells. Fish. Sci 2005, 71, 459–461. [Google Scholar]
  72. Kotake-Nara, E; Terasaki, M; Nagao, A. Characterization of apoptosis induced by fucoxanthin in human promyelocytic leukemia cells. Biosci. Biotechnol. Biochem 2005, 69, 224–227. [Google Scholar]
  73. Ganesan, P; Noda, K; Manabe, Y; Ohkubo, T; Tanaka, Y; Maoka, T; Sugawara, T; Hirata, T. Siphonaxanthin, a marine carotenoid from green algae, effectively induces apoptosis in human leukemia (HL-60) cells. Biochim. Biophys. Acta 2011, 1810, 497–503. [Google Scholar]
  74. Das, SK; Hashimoto, T; Shimizu, K; Yoshida, T; Sakai, T; Sowa, Y; Komoto, A; Kanazawa, K. Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. Biochim. Biophys. Acta 2005, 1726, 328–335. [Google Scholar]
  75. Kotake-Nara, E; Asai, A; Nagao, A. Neoxanthin and fucoxanthin induce apoptosis in PC-3 human prostate cancer cells. Cancer Lett 2005, 220, 75–84. [Google Scholar]
  76. Satomi, Y; Nishino, H. Fucoxanthin, a natural carotenoid, induces G1 arrest and GADD45 gene expression in human cancer cells. Vivo 2007, 21, 305–309. [Google Scholar]
  77. Satomi, Y; Nishino, H. Implication of mitogen-activated protein kinase in the induction of G1 cell cycle arrest and gadd45 expression by the carotenoid fucoxanthin in human cancer cells. Biochim. Biophys. Acta 2009, 1790, 260–266. [Google Scholar]
  78. Yu, RX; Hu, XM; Xu, SQ; Jiang, ZJ; Yang, W. Effects of fucoxanthin on proliferation and apoptosis in human gastric adenocarcinoma MGC-803 cells via JAK/STAT signal pathway. Eur. J. Pharmacol 2011, 657, 10–19. [Google Scholar]
  79. Okuzumi, J; Nishino, H; Murakoshi, M; Iwashima, A; Tanaka, Y; Yamane, T; Fujita, Y; Takahashi, T. Inhibitory effects of fucoxanthin, a natural carotenoid, on N-myc expression and cell cycle progression in human malignant tumor cells. Cancer Lett 1990, 55, 75–81. [Google Scholar]
  80. Das, SK; Hashimoto, T; Baba, M; Nishino, H; Komoto, A; Kanazawa, K. Japanese kelp (kombu) extract suppressed the formation of aberrant crypt foci in azoxymethane challenged mouse colon. J. Clin. Biochem. Nutr 2006, 38, 119–125. [Google Scholar]
  81. Kim, JM; Araki, S; Kim, DJ; Park, CB; Takasuka, N; Baba-Toriyama, H; Ota, T; Nir, Z; Khachik, F; Shimidzu, N; Tanaka, Y; Osawa, T; Uraji, T; Murakoshi, M; Nishino, H; Tsuda, H. Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-dimethylhydrazine initiation. Carcinogenesis 1998, 19, 81–85. [Google Scholar]
  82. Okuzumi, J; Takahashi, T; Yamane, T; Kitao, Y; Inagake, M; Ohya, K; Tanaka, Y. Inhibitory effects of fucoxanthin, a natural carotenoid, on N-ethyl-N′-nitro-N-nitrosoguanidine-induced mouse duodenal carcinogenesis. Cancer Lett 1993, 68, 159–168. [Google Scholar]
  83. Miyashita, K; Nishikawa, S; Beppu, F; Tsukui, T; Abe, M; Hosokawa, M. The allenic carotenoid fucoxanthin, a novel marine nutraceutical from brown seaweeds. J. Sci. Food Agric 2011, 91, 1166–1174. [Google Scholar]
  84. Maeda, H; Hosokawa, M; Sashima, T; Takahashi, N; Kawada, T; Miyashita, K. Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Int. J. Mol. Med 2006, 18, 147–152. [Google Scholar]
  85. Park, HJ; Lee, MK; Park, YB; Shin, YC; Choi, MS. Beneficial effects of Undaria pinnatifida ethanol extract on diet-induced-insulin resistance in C57BL/6J mice. Food Chem. Toxicol 2011, 49, 727–733. [Google Scholar]
  86. Maeda, H; Tsukui, T; Sashima, T; Hosokawa, M; Miyashita, K. Seaweed carotenoid, fucoxanthin, as a multi-functional nutrient. Asia Pac. J. Clin. Nutr 2008, 17, 196–199. [Google Scholar]
  87. Woo, MN; Jeon, SM; Shin, YC; Lee, MK; Kang, MA; Choi, MS. Anti-obese property of fucoxanthin is partly mediated by altering lipid-regulating enzymes and uncoupling proteins of visceral adipose tissue in mice. Mol. Nutr. Food Res 2009, 53, 1603–1611. [Google Scholar]
  88. Jeon, SM; Kim, HJ; Woo, MN; Lee, MK; Shin, YC; Park, YB; Choi, MS. Fucoxanthin-rich seaweed extract suppresses body weight gain and improves lipid metabolism in high-fat-fed C57BL/6J mice. Biotechnol. J 2010, 5, 961–969. [Google Scholar]
  89. Maeda, H; Hosokawa, M; Sashima, T; Murakami-Funayama, K; Miyashita, K. Anti-obesity and anti-diabetic effects of fucoxanthin on diet-induced obesity conditions in a murine model. Mol. Med. Rep 2009, 2, 897–902. [Google Scholar]
  90. Hosokawa, M; Miyashita, T; Nishikawa, S; Emi, S; Tsukui, T; Beppu, F; Okada, T; Miyashita, K. Fucoxanthin regulates adipocytokine mRNA expression in white adipose tissue of diabetic/obese KK-Ay mice. Arch. Biochem. Biophys 2010, 504, 17–25. [Google Scholar]
  91. Matsumoto, M; Hosokawa, M; Matsukawa, N; Hagio, M; Shinoki, A; Nishimukai, M; Miyashita, K; Yajima, T; Hara, H. Suppressive effects of the marine carotenoids, fucoxanthin and fucoxanthinol on triglyceride absorption in lymph duct-cannulated rats. Eur. J. Nutr 2010, 49, 243–249. [Google Scholar]
  92. Miyashita, K; Maeda, H; Okada, T; Abe, M; Hosokawa, M. Anti-obesity and anti-diabetic effects of allenic carotenoid, fucoxanthin. Agro. Food Ind. Hi Tech 2010, 21, 24–27. [Google Scholar]
  93. Sugawara, T; Matsubara, K; Akagi, R; Mori, M; Hirata, T. Antiangiogenic activity of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. J. Agric. Food Chem 2006, 54, 9805–9810. [Google Scholar]
  94. Yim, MJ; Hosokawa, M; Mizushina, Y; Yoshida, H; Saito, Y; Miyashita, K. Suppressive effects of amarouciaxanthin A on 3T3-L1 adipocyte differentiation through down-regulation of PPARγ and C/EBPα mRNA expression. J. Agric. Food Chem 2011, 59, 1646–1652. [Google Scholar]
  95. Kang, SI; Ko, HC; Shin, HS; Kim, HM; Hong, YS; Lee, NH; Kim, SJ. Fucoxanthin exerts differing effects on 3T3-L1 cells according to differentiation stage and inhibits glucose uptake in mature adipocytes. Biochem. Biophys. Res. Commun 2011, 409, 769–774. [Google Scholar]
  96. Okada, T; Nakai, M; Maeda, H; Hosokawa, M; Sashima, T; Miyashita, K. Suppressive effect of neoxanthin on the differentiation of 3T3-L1 adipose cells. J. Oleo Sci 2008, 57, 345–351. [Google Scholar]
  97. Tsukui, T; Konno, K; Hosokawa, M; Maeda, H; Sashima, T; Miyashita, K. Fucoxanthin and fucoxanthinol enhance the amount of docosahexaenoic acid in the liver of KKAy obese/diabetic mice. J. Agric. Food Chem 2007, 55, 5025–5029. [Google Scholar]
  98. Liu, CL; Liang, AL; Hu, ML. Protective effects of fucoxanthin against ferric nitrilotriacetate-induced oxidative stress in murine hepatic BNL CL.2 cells. Toxicol. Vitro 2011, 25, 1314–1319. [Google Scholar]
  99. Heo, SJ; Jeon, YJ. Protective effect of fucoxanthin isolated from Sargassum siliquastrum on UV-B induced cell damage. J. Photochem. Photobiol. B 2009, 95, 101–107. [Google Scholar]
  100. Urikura, I; Sugawara, T; Hirata, T. Protective effect of fucoxanthin against UVB-induced skin photoaging in hairless mice. Biosci. Biotechnol. Biochem 2011, 75, 757–760. [Google Scholar]
  101. Shimoda, H; Tanaka, J; Shan, SJ; Maoka, T. Anti-pigmentary activity of fucoxanthin and its influence on skin mRNA expression of melanogenic molecules. J. Pharm. Pharmacol 2010, 62, 1137–1145. [Google Scholar]
  102. Van Tenten, Y; Schuitmaker, HJ; De Wolf, A; Willekens, B; Vrensen, GFJM; Tassignon, MJ. The effect of photodynamic therapy with bacteriochlorin a on lens epithelial cells in a capsular bag model. Exp. Eye Res 2001, 72, 41–48. [Google Scholar]
  103. Shiratori, K; Ohgami, K; Ilieva, I; Jin, XH; Koyama, Y; Miyashita, K; Yoshida, K; Kase, S; Ohno, S. Effects of fucoxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Exp. Eye Res 2005, 81, 422–428. [Google Scholar]
Marinedrugs 09 01806f1 1024
Figure 1. Structures of fucoxanthin and its metabolites fucoxanthinol, amarouciaxanthin A, and halocynthiaxanthin.

Click here to enlarge figure

Figure 1. Structures of fucoxanthin and its metabolites fucoxanthinol, amarouciaxanthin A, and halocynthiaxanthin.
Marinedrugs 09 01806f1 1024
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert